S. Ortiz

发表

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

C. Caracta, K. Lasseter, E. Garcia Gil, 2012, Pulmonary pharmacology & therapeutics.

Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.

C. Caracta, E. G. Gil, Fanying Li, 2012, Biopharmaceutics & drug disposition.

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

G. Ariceta, B. Dixon, E. Rondeau, 2019, Blood.

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

L. Greenbaum, N. Fujita, M. Ogawa, 2020, Pediatric Nephrology.

Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up

J. Szer, F. Şahin, W. Füreder, 2022, Advances in Therapy.

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

R. Wells, J. Szer, A. Risitano, 2020, British journal of haematology.

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

R. Wells, J. Szer, A. Risitano, 2019, Blood.

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

J. Maciejewski, J. Szer, Peng Liu, 2020, Haematologica.

Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019

S. Kazani, A. McEneny-King, J. Monteleone, 2021, Infectious Diseases and Therapy.

Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide

R. Busby, S. Ortiz, 2014, Digestive Diseases and Sciences.

Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series

S. Kazani, M. Naqvi, M. Zakowski, 2022, American journal of reproductive immunology.

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

N. Heyne, Y. Miyakawa, G. Ariceta, 2020, Kidney international.

One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

R. Wells, A. Bosi, A. Gaya, 2020, European journal of haematology.

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

J. Maciejewski, J. Szer, A. Risitano, 2018, Blood.

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

R. Wells, J. Szer, A. Risitano, 2018, Blood.

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study

R. Wells, H. Schrezenmeier, G. Socié, 2020, Therapeutic advances in hematology.

S863 ONE-YEAR EFFICACY OF RAVULIZUMAB (ALXN1210) IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAIVE TO COMPLEMENT INHIBITORS

R. Wells, H. Schrezenmeier, G. Socié, 2019, HemaSphere.

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis

D. Annane, R. Mantegazza, J. Howard, 2023, Journal of Neurology.

Effects of Commonly Administered Agents and Genetics on Nebivolol Pharmacokinetics: Drug‐Drug Interaction Studies

J. Gorski, C. Lindamood, S. Ortiz, 2011, Journal of clinical pharmacology.

A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State

P. Ghahramani, H. M. Wright, D. Desai-Krieger, 2015, American journal of therapeutics.

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

H. Cheong, G. Ariceta, B. Dixon, 2020, Kidney international.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

K. Schmid, S. Pascual, J. Jansat, 2010, Clinical therapeutics.

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants

C. Caracta, Stephen Flach, J. Jansat, 2012, Journal of clinical pharmacology.

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

R. Wells, A. Bosi, A. Gaya, 2019, Blood.

Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder During the Phase 3 CHAMPION-NMOSD trial (S5.004)

H. Kim, C. O. Guevara, S. Pittock, 2023, Sunday, April 23.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

E. G. Gil, K. Schmid, S. Pascual, 2010, Clinical therapeutics.